Ultragenyx Pharmaceutical Inc. Files Q1 2025 10-Q
Ticker: RARE · Form: 10-Q · Filed: May 7, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials
TL;DR
**Ultragenyx Q1 2025 10-Q filed. Check financials.**
AI Summary
Ultragenyx Pharmaceutical Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and disclosures relevant to investors are presented in this report.
Why It Matters
This 10-Q filing provides investors with the latest financial and operational details for Ultragenyx Pharmaceutical Inc., crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Ultragenyx faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- Novato, CA (location) — Company headquarters
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 7, 2025.
What is Ultragenyx Pharmaceutical Inc.'s Standard Industrial Classification code?
Ultragenyx Pharmaceutical Inc.'s Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Where is Ultragenyx Pharmaceutical Inc. headquartered?
Ultragenyx Pharmaceutical Inc. is headquartered at 60 Leveroni Court, Novato, CA 94949.
What is the SEC file number for Ultragenyx Pharmaceutical Inc.?
The SEC file number for Ultragenyx Pharmaceutical Inc. is 001-36276.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).